Search hospitals > Maine > Scarborough
Maine Children's Cancer Program
Claim this profileScarborough, Maine 04074
Global Leader in Leukemia
Global Leader in Tumors
Conducts research for Lymphoblastic Leukemia-Lymphoma
Conducts research for Lymphoma
Conducts research for Brain Tumor
130 reported clinical trials
6 medical researchers
Summary
Maine Children's Cancer Program is a medical facility located in Scarborough, Maine. This center is recognized for care of Leukemia, Tumors, Lymphoblastic Leukemia-Lymphoma, Lymphoma, Brain Tumor and other specialties. Maine Children's Cancer Program is involved with conducting 130 clinical trials across 268 conditions. There are 6 research doctors associated with this hospital, such as Eric C. Larsen, Aaron R. Weiss, Stanley Chaleff, MD, and Roger C. Inhorn.Area of expertise
1Leukemia
Global LeaderStage II
Stage IV
Stage III
2Tumors
Global LeaderStage IV
Stage I
Stage II
Top PIs
Eric C. LarsenMaine Children's Cancer Program7 years of reported clinical research
Studies Lymphoma
Studies Leukemia
24 reported clinical trials
67 drugs studied
Aaron R. WeissMaine Children's Cancer Program3 years of reported clinical research
Studies Tumors
Studies Rhabdomyosarcoma
9 reported clinical trials
27 drugs studied
Stanley Chaleff, MDMaine Children's Cancer Program4 years of reported clinical research
Studies Brain Tumor
Studies Low Grade Glioma
6 reported clinical trials
14 drugs studied
Roger C. InhornPenobscot Bay Medical Center9 years of reported clinical research
Studies Cancer
Studies Colorectal Cancer
4 reported clinical trials
45 drugs studied
Clinical Trials running at Maine Children's Cancer Program
Brain Tumor
Osteosarcoma
Germ Cell Tumors
Astrocytoma
Non-Hodgkin's Lymphoma
Tumors
Acute Lymphoblastic Leukemia
Lymphoma
Rhabdomyosarcoma
Low Grade Glioma
Selumetinib + Vinblastine
for Low-Grade Glioma
This phase III trial investigates the best dose of vinblastine in combination with selumetinib and the benefit of adding vinblastine to selumetinib compared to selumetinib alone in treating children and young adults with low-grade glioma (a common type of brain cancer) that has come back after prior treatment (recurrent) or does not respond to therapy (progressive). Selumetinib is a drug that works by blocking a protein that lets tumor cells grow without stopping. Vinblastine blocks cell growth by stopping cell division and may kill cancer cells. Giving selumetinib in combination with vinblastine may work better than selumetinib alone in treating recurrent or progressive low-grade glioma.
Recruiting2 awards Phase 339 criteria
Selumetinib vs Carboplatin/Vincristine
for Brain Cancer
This phase III trial studies if selumetinib works just as well as the standard treatment with carboplatin/vincristine (CV) for subjects with NF1-associated low grade glioma (LGG), and to see if selumetinib is better than CV in improving vision in subjects with LGG of the optic pathway (vision nerves). Selumetinib is a drug that works by blocking some enzymes that low-grade glioma tumor cells need for their growth. This results in killing tumor cells. Drugs used as chemotherapy, such as carboplatin and vincristine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether selumetinib works better in treating patients with NF1-associated low-grade glioma compared to standard therapy with carboplatin and vincristine.
Recruiting2 awards Phase 328 criteria
Selumetinib vs. Chemotherapy
for Brain Cancer
This trial is comparing a new drug, selumetinib, with standard chemotherapy to treat patients with a specific type of brain tumor. The patients do not have a certain genetic mutation and are not affected by a genetic disorder. Selumetinib works by blocking enzymes needed for tumor growth, while the standard drugs kill or stop tumor cells from dividing.
Recruiting2 awards Phase 3
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Maine Children's Cancer Program?
Maine Children's Cancer Program is a medical facility located in Scarborough, Maine. This center is recognized for care of Leukemia, Tumors, Lymphoblastic Leukemia-Lymphoma, Lymphoma, Brain Tumor and other specialties. Maine Children's Cancer Program is involved with conducting 130 clinical trials across 268 conditions. There are 6 research doctors associated with this hospital, such as Eric C. Larsen, Aaron R. Weiss, Stanley Chaleff, MD, and Roger C. Inhorn.